It may be that Recaf initially had its difficulties but maybe Abbott also had difficulties with other parameters of this multi panel test. The solution was to rewrite the agreement such that both Abbott and Biocurex could independantly solve the issues from each side. Now that all issues are solved, its time to rumble. It is to ironic that Abbott is presenting the Biomarker panel in Spain.